137 results
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
2 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
6:03am
discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200 to maintain its development momentum. As previously …
License, collaboration and royalty revenue
Total revenue, net
Operating expenses
Cost of sales
Selling, general and administrative
Research and development
8-K
AUPH
Aurinia Pharmaceuticals Inc
29 Feb 24
Departure of Directors or Certain Officers
4:10pm
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Executive Vice President, Research and Development
8-K
iv2mmr848a
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
8-K
EX-99.1
a3k90lgal h4
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
8-K
EX-99.1
bfur pl2hr24qj5
2 Nov 23
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
6:01am
8-K
EX-99.1
5bmzgp tgm5y31n4b
3 Aug 23
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
6:03am
8-K
EX-99.1
dzz1z8rzdx
4 May 23
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
6:06am
PX14A6G
by74 9el3kf9tdyxcc5
26 Apr 23
Letter to shareholders
10:20am
8-K
EX-99.1
znneeawgb
3 Nov 22
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
6:04am